Aims: BRCA mutation (BRCAmut) testing is an important tool for the risk assessment, prevention and early diagnosis of breast cancer (BC) and ovarian cancer (OC), and more recently, for determining patient susceptibility to targeted therapy. This study assessed the current BRCAmut testing patterns and explored physicians' perspectives on the utilities and optimal sequencing of the testing, in order to facilitate and standardize testing practices.
BACKGROUND
Ovarian cancer (OC) has been pathologically associated with genetic mutations that result in a homologous recombination (HR) deficiency in DNA repair. High-and low-grade OCs, as well as their subtypes, have been associated with different HR mutations. [1] [2] [3] Approximately 50% of high-grade serous epithelial ovarian cancers (HGSOCs) have alterations in HR repair genes, including BRCA1 and BRCA2. 4 The prevalence of BRCA mutation (BRCAmut) in HGSOC has been reported to be ∼11% for germline mutations 5 and ∼20% for germline and somatic mutations combined. 6 Moreover, in BRCA-mutated OC, the levels of the poly(ADP-ribose) polymerase (PARP) that is involved in DNA repair are elevated. 7 Genetic testing for BRCAmut is an important tool for assessing the risks of developing breast cancer (BC) and OC in individuals, particularly as germline BRCAmut can be inherited. Testing is also useful for early detection of the diseases, and enables BRCAmut-positive individuals to consider undertaking risk-reducing measures such as mastectomy (surgical removal of the breast) and/or salpingo-oophorectomy (surgical removal of the fallopian tube and ovary). Results of previous pooled analyses suggested that BRCAmut in OC patients were associated with improved survival (without excluding the potential effect of screening in leading to early detection and treatment) in both BRCA1 and BRCA2 mutation carriers. 8, 9 Bolton 8 reported improved 5-year survival in 26 studies (including one study from Hong Kong):
for BRCA1-mutated (n = 1213) versus wild-type (n = 2666) carriers, the hazard ratio (HR) = 0.78 (95% confidence interval [CI] : 0.68-0.89, P = 0.002); for BRCA2-mutated versus wild-type carriers, the HR = 0.61 (95% CI: 0.50-0.76, P = 0.00006). In meta-analyses, 10, 11 risk-reducing salpingo-oophorectomy was also significantly associated with reductions in all-cause OC and BC mortalities.
BRCAmut testing has also been implicated in cancer therapy planning, since the recent introduction of targeted therapies such as the PARP inhibitor (PARPi) olaparib, which was approved by the US Food and Drug Administration in December 2014 for the treatment of advanced OC with BRCAmut, and in August 2017 for the maintenance treatment of platinum-sensitive ovarian, fallopian tube or primary peritoneal cancers. 12 In the phase 2 trial of olaparib for platinumsensitive recurrent serous OC (n = 136) versus placebo (n = 129), significant improvements in median progression-free survival were observed in the overall population: 11.2 versus 4.3 months (HR = 0.18; 95% CI: 0.10-0.31, P < 0.0001). 13 A median overall survival (OS) advantage versus placebo was also reported for patients who were BRCAmut-positive (n = 136), although it was not significant at the prespecified level (34.9 vs 30.2 months; HR = 0.62; 95% CI: 0.41-0.94, P = 0.025). 14 There is a certain amount of variation in the international guideline recommendations for patient selection for BRCAmut testing, but they also share important key points. First, several guidelines, including those from the American Society of Clinical Oncology 2014 15 48 The HKAM guidelines were in many ways similar to the NCCN guidelines, but without the more recent update on testing all OCs. The CHP guidelines were also in line with the international guidelines in recommending the consideration of BRCAmut testing for those at high risk from FH, particularly those who have firstdegree relatives with confirmed BRCAmut status. The CHP guidelines also recommended that confirmed BRCAmut carriers may consider undergoing prophylactic surgeries.
In view of the reported variations and insufficiencies described above, the primary objectives of the present study were to: (1) assess the current practice patterns of BRCAmut testing referrals in Hong Kong; and (2) elucidate potential suggestions for effective testing implementation. The secondary objectives were to compare testing patterns between: (1) testing practices in Hong Kong and those recently reported in the international literature; and (2) survey respondents (Hong Kong-based physicians in relevant specialties) and expert panelists (physicians with extensive BRCAmut testing experience). It is our aim that this study will provide practical insights for improving BRCAmut testing referrals in Hong Kong, smoothing workflow and enabling more patients who are at risk to benefit from testing.
METHODS

Literature search
A literature search for articles on BRCAmut testing for OC was conducted using a combination of the keywords "BRCA," "ovarian cancer," "survey" and "guideline" in the PubMed, ClinicalKey, ProQuest, EMBASE and Google Scholar databases for the years 2007-2018 (i.e. past 10 years). A total of 174 articles that were considered relevant to our study were selected and retrieved. The survey questionnaire and voting questions (see below) were developed with specific references to this literature.
Specialist survey
A questionnaire comprising 21 questions was developed to cover the practical details of BRCAmut testing referrals in Hong Kong 
Expert meeting
RESULTS
Survey responses
A total of 71 specialists completed the survey. The basic demographics of the respondents are shown in Table 1 About 33.8% of respondents would refer germline testing only (Q8). Overall, germline testing was referred more often, sometimes in parallel with somatic testing. However, the results suggested that for patients who underwent somatic testing alone and received a positive result, germline testing usually followed (Q8 
Expert meeting voting results
The eight experts were specialists in breast surgery (n = 1), clinical oncology (n = 4), gynecologic oncology (n = 1), medical oncology (n = 1) and obstetrics and gynecology (n = 1). The voting questions (V1-V10) and results are provided in Appendix B. The results that reached consensus (≥80% of votes falling on the highest two ratings on a scale or on a single answer) are highlighted as follows. In terms of patient selection, there was strong consensus on "family history of breast/ovarian cancer" (V1a), "first-degree relative with confirmed BRCA mutation" (V1c) and "early onset of breast/ovarian cancer (diagnosed at age ≤ 45)" (V1d) being important factors in the selection of patients for BRCAmut testing. The panelists also agreed that germline testing should be offered to patients who test positive for somatic BRCAmuts (V2), and unanimously agreed that genetic counseling should be offered both before and after testing (V8).
Overall, the panelists agreed that BRCAmut testing adds positive value to the optimization of patient care (V9) and to patients' understanding and management of their individual and familial risks (V10). In terms of major considerations for successful testing implementation, "improved access to testing facilities" (V6a), "improved access to genetic counseling services" (V6b) and "improved cost or affordability" (V6e) were most strongly voted as being helpful to the successful implementation of BRCAmut testing in Hong Kong. With regard to the physicians' knowledge and experience of the patient perspective, there was strong consensus on "potential hereditary implications" (V7b) and "financial affordability" (V7d) being important factors for patient decision making on BRCAmut testing.
DISCUSSION
Recall that the primary objectives of the study were to: (1) assess the current practice patterns of BRCAmut testing referrals in Hong Kong;
and (2) 
Patient selection
The physician's estimation of the patient's risk of OC is a strong predictor of the physician's adherence to guideline recommendations. 36 To convince physicians on the benefit of broadened testing, the expansion of selection criteria will need to be supported by evidence of an 
Germline versus somatic testing
For patients with diagnosed BC and/or OC, the panelists generally favored somatic testing before germline testing. The panelists noted that at the time of BC and/or OC diagnosis, the patient may already be experiencing a certain level of stress from knowing his/her condition and from considering the treatment options. For the first BRCAmut test, it would be easier for the patient to base his/her decision for testing on treatment planning alone rather than also having to consider the hereditary implications. A germline test could be considered after a treatment decision had been made. A disadvantage of this approach could be that the cascade testing of family members might be more easily missed or forgotten.
However, contrary evidence from the literature shows that many patients who were referred testing at a later time after initial diagnosis indicated that they would have preferred earlier testing. 51 Insurance coverage was also not a significant consideration in patients' decision to undergo testing. 52 In a retrospective study of an online survey of 1282 women with a personal history of OC referred for BRCAmut testing, 53 the strongest factors that affected their testing decisions were concern for family members (89.6%), healthcare provider recommendations (76.3%) and concern about the risk of other cancers (72.6%), suggesting that most patients are concerned about the well-being of their family members in relation to their own diagnosed condition.
Our panelists commented that, generally, for patients with a BC and/or OC diagnosis, performing somatic testing first would likely be more cost-saving than the reverse option, since patients who were tested somatic-negative would not require further germline testing. In deciding between germline and/or somatic testing, it would be reasonable to look at the FH (if any), age and pathology from a genetic point of view, that is using a risk-adapted approach. In fact, if the case was unlikely to be germline-mutated, performing both tests would be desirable for ruling out the familial risks. 
Timing of testing
Choice of facilities
Although cost appears to be a major issue for affecting the implementation of BRCAmut testing in Hong Kong, the selection of an accredited facility for testing is also very important. For reliable results, the testing facility should be accredited specifically for next-generation sequencing testing technology. According to the panelists, local testing facilities in Hong Kong have been continuously revalidating their results with local samples and data, in collaboration with overseas institutions, to arrive at a reasonable level of accuracy. For somatic testing, the accuracy of the results can be even more difficult to determine than for germline testing, since fewer past data are available. As multigene panel testing becomes more common, it may potentially improve the cost-and time-effectiveness compared with single-gene testing. 55 However, multigene panel testing will more often lead to the identification of uncertain mutations, 56 and any broader population-based testing of a widened spectrum of cancer susceptibility genes may require further cost-benefit justification. 57 Mutations may be classified into categories according to their estimated pathogenicity. 58, 59 Our panelists suggested the following steps for determining the pathogenic risk of uncertain mutations: (1) in a single individual, it is usually sufficient to prove the significance of one mutation indicating BRCAmut status; (2) use bioinformatic analyses and search international databases; (3) compare with local controls, as the rarer the mutation in local BRCAmut-positive patients, the more unlikely it is to be of pathogenic significance; and (4) perform a familial cosegregation analysis. According to our panelists' experience, these four steps could clarify approximately one-third of the variant of uncertain significance mutations, while leaving two-thirds undefined.
Genetic counseling
While our experts unanimously suggested providing genetic counseling both before and after BRCAmut testing (V8), the survey results showed that 14.1% of specialists do not provide genetic counseling to patients who undergo BRCAmut testing (Q9). Physicians may sometimes perceive the distance to a genetic counseling appointment as a barrier. 60 Various studies have recognized the difficulties in testing implementation with regard to assimilating BRCAmut testing and genetic counseling into the overall healthcare service environment, and devised sundry solutions in response. 61 For example, Bayraktar and Arun 54 suggest integrating genetic assessment into the management of patients who are receiving neoadjuvant chemotherapy, given the usual turnaround time of BRCAmut testing (3-4 weeks).
The utility of genetic counseling in facilitating BRCAmut testing is also becoming more widely recognized, 62 65 Likewise, Kentwell et al. 66 incorporated routine germline testing into a specialized cancer clinic that featured an embedded genetic counselor during chemotherapy chair time, which increased referral rates significantly.
Our experts suggested several innovative, structured arrangements in genetic counseling that included group counseling and video counseling to facilitate the patients' basic understanding of BRCAmut testing and improve workflow efficiency. It was noted that lengthy counseling wait-time was partly delaying testing, too. Traditional individualized counseling appeared unfeasible these days, given the growing popularity of BRCAmut testing. On the other hand, counseling provided directly by an oncologist might benefit treatment planning.
Group counseling could explain the basic science and principles of 67 reported that many patients actually preferred to undergo testing without prior face-to-face counseling. A group or video counseling session before testing may be more comfortable for patients, while providing the necessary basic information to familiarize them with BRCAmut testing.
Limitations
The present study is limited by its relatively small survey sample size, although efforts were made to reach out to as many relevant specialists as time and manpower allowed. The small numbers did not enable any further stratified analyses of the results. The outcomes of the panel discussion were qualitative in nature, without supplying any quantitative economical evaluation of the cost-effectiveness of BRCAmut testing.
We chose the Delphi method to arrive at agreements in a transparent and quantifiable manner. It is our belief that, given the complexity of the issues as well as the genetic variability and practical subtleties across different regions of the world, the facilitation of analytic discussions on localized real-life situations such as the one we have presented here is necessary. Future studies in Hong Kong may research the outcomes and effectiveness of testing programs, and a study of the above-mentioned video counseling concept is being undertaken by the Hong Kong Hereditary Breast Cancer Family Registry.
CONCLUSIONS
Over the years, the usefulness of BRCAmut testing has gradually become recognized in Hong Kong's healthcare setting, and demand for testing has grown with the emergence of targeted therapy for OC.
Accessibility of BRCAmut testing to all at-risk populations will be eventually achievable through improvements in testing affordability, as well as widened availability of accredited testing and genetic counseling facilities.
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